Want to join the conversation?
$CELG said in addition to the EU, REVLIMID is indicated for treating patients with relapsed/refractory MCL in the US, Switzerland, Israel, Turkey, Australia and some countries in Latin America. REVLIMID is also indicated in some countries including the EU for treating multiple myeloma and myelodysplastic syndromes.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.